<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969525</url>
  </required_header>
  <id_info>
    <org_study_id>PA0008</org_study_id>
    <secondary_id>2016-001103-23</secondary_id>
    <nct_id>NCT02969525</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis.</brief_title>
  <official_title>A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the dose response based on the efficacy, safety and tolerability
      of bimekizumab in subjects with active psoriatic arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosage regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosage regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosage regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimekizumab dosage regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimekizumab</intervention_name>
    <description>Bimekizumab in different dosage regimens.</description>
    <arm_group_label>Bimekizumab dosage regimen 1</arm_group_label>
    <arm_group_label>Bimekizumab dosage regimen 2</arm_group_label>
    <arm_group_label>Bimekizumab dosage regimen 3</arm_group_label>
    <arm_group_label>Bimekizumab dosage regimen 4</arm_group_label>
    <other_name>UCB4940</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a documented diagnosis of adult-onset PsA classified by Classification
             Criteria for Psoriatic Arthritis (CASPAR) criteria with symptoms for at least 6 months
             prior to Screening, with active psoriatic arthritis (PsA) at Baseline/Day 1, and must
             have at Baseline tender joint count (TJC) &gt;=3 out of 78 and swollen joint count (SJC)
             &gt;=3 out of 76

          -  Subject must be rheumatoid factor and anti-cyclic citrullinated peptide (CCP)
             antibodies negative

          -  Subject must have active psoriatic lesion(s) and/or a documented history of psoriasis

          -  Subjects who are regularly taking nonsteroidal anti-inflammatory drug (NSAIDs)/COX-2
             inhibitors as part of their PsA therapy are required to be on a stable dose/dose
             regimen for at least 14 days before Baseline

          -  Subjects taking corticosteroids must be on an average daily dose of &lt;=10mg/day
             prednisone or equivalent for at least 14 days before Baseline and should remain on a
             stable dose through the Week 16 visit

          -  Subjects taking methotrexate (MTX) (&lt;=25mg /week) are allowed to continue their
             medication if started at least 12 weeks prior to Baseline, with a stable dose for at
             least 8 weeks before randomization

          -  Subjects taking leflunomide (LEF; &lt;=20mg/day or an average of 20mg/day if not dosed
             daily) are allowed to continue their medication if started at least 3 months prior to
             Baseline, with a stable dose for at least 8 weeks before randomization. Dose and
             dosing schedule should remain stable up to Week 16

          -  Subjects may be tumor necrosis factor (TNF) inhibitor na√Øve or may have received 1
             prior TNF inhibitor. Subjects who have been on a TNF inhibitor previously must have:

               1. experienced an inadequate response to previous treatment given for at least 3
                  months

               2. been intolerant to administration (eg, had a side-effect/adverse event (AE) that
                  led to discontinuation)

               3. lost access to TNF inhibitor for other reasons

        Exclusion Criteria:

          -  Subjects with any current sign or symptom that may indicate an active infection (with
             the exception of the common cold) or has had an infection requiring systemic
             antibiotics within 2 weeks of Baseline/Day 1

          -  Subjects with a history of chronic or recurrent infections, or a serious or
             life-threatening infection within the 6 months prior to the Baseline Visit

          -  Subjects with concurrent acute or chronic viral hepatitis B or C or human
             immunodeficiency virus (HIV) infection

          -  Subjects with known history of or current clinically active infection with
             Histoplasma, Coccidioides, Paracoccidioides, Pneumocystis, Blastomyces, or Aspergillus
             or current active Candidiasis

          -  Subjects receiving any live (includes attenuated) vaccination within the 8 weeks prior
             to Baseline

          -  Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB
             infection, with latent TB infection (LTBI), or current or history of nontuberculous
             mycobacteria (NTMB) infection

          -  Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic
             arthritis

          -  Subjects with concurrent malignancy or a history of malignancy during the past 5 years
             will be excluded, with following exceptions that may be included:

               1. &lt;= 3 excised or ablated basal cell carcinomas of the skin

               2. One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised,
                  or ablated only (other treatments, ie, chemotherapy, do not apply), with no signs
                  of recurrence or metastases for more than 2 years prior to Screening

               3. Actinic keratosis (-es)

               4. Squamous cell carcinoma-in-situ of the skin successfully excised, or ablated,
                  more than 6 months prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273(UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pa0008 007</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 005</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 011</name>
      <address>
        <city>Lansing</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 025</name>
      <address>
        <city>Lexington</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 014</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 001</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 003</name>
      <address>
        <city>Hagerstown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 012</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 004</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 010</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 006</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 013</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 002</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 205</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 207</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 210</name>
      <address>
        <city>Praha 11</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 202</name>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 201</name>
      <address>
        <city>Praha 4</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 209</name>
      <address>
        <city>Praha 4</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 203</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 302</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 309</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 304</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 301</name>
      <address>
        <city>Ratingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 403</name>
      <address>
        <city>Budakeszierdo</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 401</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 452</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 453</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 456</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 455</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 451</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 450</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 454</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 459</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 465</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 604</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 605</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 607</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 606</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pa0008 608</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>PsA</keyword>
  <keyword>Bimekizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

